Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Foscarnet decreases HIV-1 plasma load.
Devianne-Garrigue I, Pellegrin I, Denisi R, Dupon M, Ragnaud JM, Barbeau P, Breilh D, Leng B, Fleury HJ, Pellegrin JL. Devianne-Garrigue I, et al. Among authors: breilh d. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 May 1;18(1):46-50. doi: 10.1097/00042560-199805010-00007. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9593457
Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.
Wittkop L, Breilh D, Da Silva D, Duffau P, Mercié P, Raymond I, Anies G, Fleury H, Saux MC, Dabis F, Fagard C, Thiébaut R, Masquelier B, Pellegrin I; ANRS CO3 Aquitaine Cohort. Wittkop L, et al. Among authors: breilh d. J Antimicrob Chemother. 2009 Jun;63(6):1251-5. doi: 10.1093/jac/dkp114. Epub 2009 Mar 31. J Antimicrob Chemother. 2009. PMID: 19336453 Free PMC article. Clinical Trial.
Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F, Fleury H; Groupe d' Epidémiologie Clinique du SIDA en Aquitaine. Masquelier B, et al. Among authors: breilh d. Antimicrob Agents Chemother. 2002 Sep;46(9):2926-32. doi: 10.1128/AAC.46.9.2926-2932.2002. Antimicrob Agents Chemother. 2002. PMID: 12183249 Free PMC article. Clinical Trial.
Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).
Djabarouti S, Breilh D, Pellegrin I, Lavit M, Camou F, Caubet O, Fleury H, Saux MC, Pellegrin JL. Djabarouti S, et al. Among authors: breilh d. J Antimicrob Chemother. 2006 Nov;58(5):1090-3. doi: 10.1093/jac/dkl348. Epub 2006 Aug 18. J Antimicrob Chemother. 2006. PMID: 16921181
Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.
Breilh D, Djabarouti S, Trimoulet P, Le Bail B, Dupon M, Ragnaud JM, Fleury H, Saux MC, Thiébaut R, Chêne G, Neau D. Breilh D, et al. J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):428-30. doi: 10.1097/QAI.0b013e3181b62858. J Acquir Immune Defic Syndr. 2009. PMID: 19858925 No abstract available.
123 results